Is Desh Rakshak overvalued or undervalued?

Understanding Desh Rakshak’s Current Valuation Metrics

As of 21 Nov 2025, Desh Rakshak’s valuation grade was revised to fair, reflecting a more balanced assessment compared to its previous expensive rating. The company’s price-to-earnings (PE) ratio stands at 37.17, which is relatively high but not uncommon in the pharmaceutical industry, where growth prospects often justify premium multiples. The price-to-book (P/B) ratio of 1.90 suggests the stock is trading at nearly twice its book value, indicating moderate investor confidence in its asset base and future earnings potential.

Enterprise value multiples further support this fair valuation stance. The EV to EBIT ratio is 23.04, while EV to EBITDA is 14.92, both figures signalling a valuation that is elevated but not excessive when compared to sector norms. The EV to sales ratio of 3.08 and EV to capital employed of 1.80 also align with a company that is fairly priced relative to its operational scale and capital efficiency.

Return metrics such as ROCE (7.79%) and ROE (5.12%) are modest, reflecting steady but not outstanding profitability. The absence of a dividend yield suggests reinvestment of earnings into growth initiatives, a common trait in pharmaceutical firms focused on innovation and pipeline development.

Peer Comparison Highlights Desh Rakshak’s Relative Position

When compared with its pharmaceutical peers, Desh Rakshak’s valuation appears reasonable. Industry giants such as Divi’s Laboratories and Torrent Pharmaceuticals are rated very expensive, with PE ratios exceeding 50 and EV to EBITDA multiples well above 30. Conversely, companies like Cipla, Dr Reddy’s Laboratories, and Zydus Lifesciences are considered attractive, trading at significantly lower PE ratios in the range of 18 to 22 and EV to EBITDA multiples around 12 to 16.

Desh Rakshak’s EV to EBITDA multiple of 14.92 places it comfortably between the expensive and attractive categories, reinforcing the fair valuation grade. This middle ground suggests the market recognises the company’s growth potential but is cautious about its current profitability and competitive pressures.

Other fair-valued peers such as Aurobindo Pharma and Alkem Laboratories have lower PE ratios and EV to EBITDA multiples, indicating that Desh Rakshak commands a premium, likely due to its superior growth trajectory or pipeline prospects.

Stock Performance and Market Sentiment

Desh Rakshak’s stock price has demonstrated remarkable returns over multiple time horizons, significantly outperforming the Sensex benchmark. Year-to-date and one-year returns exceed 150% and 180% respectively, dwarfing the Sensex’s single-digit gains. Over three years, the stock has surged over 800%, a testament to strong investor enthusiasm and company execution.

However, the recent one-month performance shows a sharp correction of nearly 28%, contrasting with the Sensex’s modest positive return. This volatility may reflect profit-taking or sector rotation, but the longer-term trend remains robust.

The stock’s 52-week high of ₹95.14 compared to the current price near ₹43 indicates a significant retracement, which may have contributed to the valuation shift from expensive to fair. This price correction could present an opportunity for investors to enter at a more reasonable valuation.

Conclusion: Fair Valuation Reflects Balanced Outlook

In summary, Desh Rakshak’s current valuation appears fair rather than overvalued or undervalued. Its elevated PE ratio and moderate profitability metrics are balanced by strong historical returns and a valuation that is reasonable relative to its peers. The recent downgrade from expensive to fair suggests the market has adjusted expectations, possibly factoring in recent price corrections and sector dynamics.

Investors considering Desh Rakshak should weigh its impressive growth track record against the inherent risks of the pharmaceutical sector, including regulatory challenges and competitive pressures. While the stock is not a bargain basement buy, it offers a compelling risk-reward profile at current levels, especially for those with a medium to long-term investment horizon.

Ultimately, Desh Rakshak’s fair valuation grade signals a stock that is priced appropriately for its fundamentals and growth prospects, making it a viable candidate for inclusion in a diversified pharmaceutical portfolio.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →